Protagonist Therapeutics PTGX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's operating income?
- Protagonist Therapeutics (PTGX) reported operating income of -$3.65M in Q1 2026.
- How has Protagonist Therapeutics's operating income changed year-over-year?
- Protagonist Therapeutics's operating income increased by 81.1% year-over-year, from -$19.31M to -$3.65M.
- What is the long-term trend for Protagonist Therapeutics's operating income?
- Over 3 years (2021 to 2025), Protagonist Therapeutics's operating income has grown at a 7.9% compound annual growth rate (CAGR), from -$125.85M to -$158.13M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.